Get the Stockscreener App
119.63
0.59%
0.70
After Hours:
119.27
-0.36
-0.30%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $119.63, with a volume of 8.32M.
It is up +0.59% in the last 24 hours and down -3.38% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$118.93
Open:
$119.285
24h Volume:
8.32M
Relative Volume:
0.71
Market Cap:
$295.77B
Revenue:
$64.93B
Net Income/Loss:
$18.26B
P/E Ratio:
16.44
EPS:
7.2751
Net Cash Flow:
$12.36B
1W Performance:
+4.77%
1M Performance:
-3.38%
6M Performance:
+52.28%
1Y Performance:
+36.56%
1-Day Range:
$118.60
$121.07
1-Week Range:
$114.02
$121.07
52-Week Range:
$73.31
$125.14
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
119.63 | 294.04B | 64.93B | 18.26B | 12.36B | 7.2751 |
LLY
Lilly Eli Co
|
878.24 | 801.34B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.45 | 576.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
209.40 | 373.42B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
188.42 | 284.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Jim Cramer on Merck & Co.: “If We’re Really Going Into an Oil Shock-Induced Slowdown, I Think This One’s Likely an Outperformer”” - Insider Monkey
Dilution adjustment of Merck & Co., Inc. – BSESOF:6MK - TradingView
[SCHEDULE 13G/A] Merck & Co., Inc. Amended Passive Investment Disclosure - Stock Titan
Mizuho downgrades Terns Pharmaceuticals stock rating on Merck deal - Investing.com
Merck Agrees to Acquire Terns for $6.7B - Contract Pharma
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE? - TradingView
Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits? - TradingView
Global X Japan Co. Ltd. Takes Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Synergy Asset Management LLC - MarketBeat
Parsons Capital Management Inc. RI Sells 14,477 Shares of Merck & Co., Inc. $MRK - MarketBeat
Brucellosis Vaccines Market is Going to Booming Growth 2026 With - openPR.com
Animal Vaccines Market Set to Boom Rapidly by 2033 | Merck & Co., - openPR.com
Dakota Wealth Management Has $19.04 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Acquired by Fort Washington Investment Advisors Inc. OH - MarketBeat
Merck & Co., Inc. stock: Strategic acquisitions and oncology focus position shares for long-term val - ad-hoc-news.de
Merck to buy Terns for $6.7 billion to grow in blood cancers - MSN
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium” - Insider Monkey
Merck’s deal for Terns sparks debate over a possible biotech bidding war - BioPharma Dive
Investors heavily search Merck & Co., Inc. (MRK): Here is what you need to know - MSN
Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up - TradingView
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
A $6.7 Billion Blockbuster Deal: Merck Bets on the CML Opportunity - Moomoo
Guggenheim reiterates Merck stock rating on Terns acquisition - Investing.com
SeaCrest Wealth Management LLC Buys 11,454 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck (MRK) Stock; Edges Higher as $6.7B Terns Acquisition Boosts Cancer Pipeline Outlook - MEXC
Merck expands haematology pipeline with $6.7bn acquisition of Terns Pharmaceuticals - European Pharmaceutical Review
Ferguson Wellman Capital Management Inc. Grows Stake in Merck & Co., Inc. $MRK - MarketBeat
Czech National Bank Raises Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Merck to purchase oncology company - The Arkansas Democrat-Gazette
Merck & Co. Inc. stock surges on Terns Pharmaceuticals acquisition and Dow Jones momentum amid marke - AD HOC NEWS
Bank of America Securities Reduces PT on Merck & Co., Inc. (MRK), Keeps a Buy Rating - MSN
Market Today: Meta/Google verdict, Arm chip, Merck-Terns deal - GuruFocus
Merck (TERN) plans tender offer to acquire Terns under March 24, 2025 merger - Stock Titan
If You Invested $1,000 in Merck & Co (MRK) - Stock Titan
Merck to Buy Terns for $6.7B to Grow in Blood Cancers - marketscreener.com
Sherwin-Williams Co., Merck share gains lead Dow's nearly 300-point jump - MSN
Merck's Deal For Terns And Its Stellar CML Drug Candidate Looks Like Good Business (MRK) - Seeking Alpha
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Merck's $6.7B Acquisition of Tern Pharmaceuticals Raises Investo - GuruFocus
Merck (NYSE:MRK) Innovation Strategy Drives S&P 500 ETF Alignment - Kalkine Media
Pharma giant Merck to acquire Terns Pharmaceuticals for $6.7 billion - marketscreener.com
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug - MedCity News
Dow's 414-Point Rally Highlighted By Gains In Merck, Amazon.Com Inc. Stocks - Moomoo
Merck Acquires Terns Pharmaceuticals for $6.7 Billion - PharmTech.com
Merck announces another pricy purchase ahead of Keytruda deadline - WFMZ.com
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Merck (MRK) Faces Mixed Reactions Following Terns Acquisition An - GuruFocus
From failure to hit to a $6.7 billion buyout: Terns Pharma gets big offer from Merck - The Business Journals
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst - Benzinga
NVIDIA Corp., Merck Share Gains Contribute To Dow's Nearly 300-Point Jump - Moomoo
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.74%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):